Peter Wirth, an executive vice president and chief legal officer for Genzyme, has been elected to the board of directors of Epix Medical, a Cambridge, MA-based MRI contrast agent developer. Wirth handles legal and corporate development for the Genzyme molecular oncology and Geltex pharmaceuticals business units.
By AuntMinnie.com staff writersAugust 30, 2001
Related Reading
Epix net loss grows in Q2, July 27, 2001
Epix trims net loss, April 27, 2001
Epix, InSightec, Brigham and Women's team up, March 12, 2001
Epix loss widens in 2000, February 16, 2001
Epix CEO joins board of contrast agent association, February 9, 2001
Copyright © 2001 AuntMinnie.com
